Insulet Corporation
Automatic drug delivery system for delivery of a GLP-1 therapeutic
Last updated:
Abstract:
The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal dosing of GLP-1 or co-formulation of GLP-1 and insulin. The size and frequency of the basal doses may be controlled by a medication delivery algorithm resident on the wearable drug delivery device based on a basal dosing history and readings from a continuous glucose monitor monitoring the glucose levels of the wearer of the device.
Status:
Grant
Type:
Utility
Filling date:
19 Feb 2021
Issue date:
2 Nov 2021